US2021161440A1PendingUtilityA1

Method and apparatus for determining a deterioration of respiratory function

36
Individually held — no corporate assignee on recordPriority: Jan 15, 2008Filed: Feb 9, 2021Published: Jun 3, 2021
Est. expiryJan 15, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Nicholas L. Taro
A61B 5/412A61B 5/14539A61B 5/0836A61B 5/1459A61B 5/14542
36
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In accordance with one embodiment of the invention, a system is provided for the monitoring of blood analytes using optical probes in the circulatory system. The probes can be inserted on the venous side of the circulatory system. In another embodiment, methods and apparatuses can be used for processing continuous information generated from indwelling intravascular or tissue optical sensors including, but not limited to, measuring gas concentrations, pH, temperature, and other analytes of blood or tissue. In another embodiment, analyte values can be displayed and analyzed to determine if the values fall outside of normal physiological parameters. Trends of one or multiple analyte values can be analyzed and extrapolated to predict any impending, deleterious condition. In one embodiment, an alarm can be transmitted to appropriate personnel when criterion/criteria are met. In yet another embodiment, devices can be inhibited from delivering continuous infusions of medicine to patients.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of monitoring at least one blood analyte for use in determining a deterioration of respiratory function, said method comprising:
 inserting an optical probe into a tissue bed of a patient;   obtaining a blood analyte measurement from said tissue bed;   determining a deterioration of respiratory function based upon said blood analyte measurement.   
     
     
         22 . The method as claimed in  claim 21  wherein said inserting said optical probe into said tissue bed of said patient comprises inserting said optical probe into an organ. 
     
     
         23 . (canceled) 
     
     
         24 . The method as claimed in  claim 21  wherein said inserting said optical probe comprises inserting said optical probe into brain tissue of said patient. 
     
     
         25 . The method as claimed in  claim 21  wherein said inserting said optical probe comprises inserting said optical probe into subcutaneous tissue of said patient. 
     
     
         26 . The method as claimed in  claim 21  wherein said inserting said optical probe comprises inserting said optical probe into a muscle of said patient. 
     
     
         27 . The method as claimed in  claim 26  wherein said inserting said optical probe comprises inserting said optical probe into a deltoid muscle of said patient. 
     
     
         28 - 51 . (canceled) 
     
     
         52 . A method comprising:
 inserting an optical fiber probe into interstitial fluid of a patient;   taking a series of interstitial fluid CO 2  measurements with the optical fiber probe;   performing a trend analysis with a processor by utilizing the series of interstitial fluid CO 2  measurements;   determining a value of the current amount of CO 2  in the respiratory system of the patient from the trend analysis;   signaling an alarm system if the value of the current amount of CO 2  in the respiratory system of the patient is in a predetermined unsafe range for CO 2 .   
     
     
         53 . A method comprising:
 inserting an optical fiber probe into interstitial fluid of a patient;   taking an interstitial fluid analyte measurement with the optical fiber probe;   utilizing a processor to determine an interstitial fluid analyte value from the interstitial fluid analyte measurement;   wherein the processor is responsive to a rule to compare the interstitial fluid analyte measurement value with a predetermined unsafe range for the interstitial fluid analyte; and   wherein the processor is responsive to a rule to signal an alarm system based upon the comparison of the interstitial fluid analyte measurement value with the predetermined unsafe range.   
     
     
         54 . The method as claimed in  claim 53  wherein the interstitial fluid analyte is CO 2 . 
     
     
         55 . The method as claimed in  claim 53  wherein the interstitial fluid analyte is pH. 
     
     
         56 . The method as claimed in  claim 53  wherein the interstitial fluid analyte is O 2 . 
     
     
         57 . The method as claimed in  claim 53  wherein the interstitial fluid analyte is pCO 2 . 
     
     
         58 . The method as claimed in  claim 53  wherein the interstitial fluid analyte is pO 2 . 
     
     
         59 . The method as claimed in  claim 53  wherein the utilizing the processor to determine the interstitial fluid analyte value from the interstitial fluid analyte measurement comprises:
 performing a trend analysis with the processor by utilizing a series of interstitial fluid CO 2  measurements. 
 
     
     
         60 . A method of decreasing the risk of postoperative opioid-induced respiratory depression comprising:
 inserting a first optical fiber probe into a peripheral venous system IV of a postoperative patient being treated with opioid(s);   utilizing an LED light source with the first optical fiber probe;   taking a series of CO 2  blood analyte measurements with the first optical fiber probe;   performing a trend analysis with a processor by utilizing the series of CO 2  blood analyte measurements;   determining a value of the current amount of CO 2  in the respiratory system of the patient from the trend analysis;   inserting a second optical fiber probe into interstitial fluid of the patient;   taking an interstitial fluid analyte measurement with the second optical fiber probe;   utilizing the processor to determine from the interstitial fluid analyte measurement a pH value for the blood of the patient;   utilizing the processor to determine from the current amount of CO 2  in the respiratory system of the patient and pH value for the blood of the patient that an increase in anerobic metabolism is occurring indicating impending respiratory failure;   in response to the determination that the increase in anerobic metabolism is occurring, signaling an alarm to life safety personnel;   in response to the determination that the increase in anerobic metabolism is occurring, inhibiting the administration of the opioid(s) to the patient;   in response to the determination that the increase in anerobic metabolism is occurring, administering medicine to cause the patient to respire more frequently.   
     
     
         61 . A method comprising:
 inserting an optical fiber probe into the venous system of a patient;   taking a venous blood analyte measurement with the optical fiber probe;   utilizing a processor to determine a venous blood analyte value from the venous blood analyte measurement;   wherein the processor is responsive to a rule to compare the venous blood analyte value with a predetermined unsafe range for the venous blood analyte; and   wherein the processor is responsive to a rule to signal an alarm system based upon the comparison of the venous blood analyte value with the predetermined unsafe range.   
     
     
         62 . The method as claimed in  claim 61  wherein the venous blood analyte is carbon dioxide in the venous blood of the patient. 
     
     
         63 . The method as claimed in  claim 61  wherein the venous blood analyte is partial pressure of oxygen in the venous blood of the patient. 
     
     
         64 . The method as claimed in  claim 61  wherein the venous blood analyte is pH of the venous blood of the patient. 
     
     
         65 . The method as claimed in  claim 61  wherein the venous blood analyte is temperature of the venous blood of the patient.

Join the waitlist — get patent alerts

Track US2021161440A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.